Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.47 |
| ▸ | BRD4 | O60885 | 10/20 | 0.47 |
| ▸ | JAK3 | P52333 | 4/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | BRD2 | P25440 | 3/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | STAT6 | P42226 | 5/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656334 | 0.90 | RPS6KA3 (0.53) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL1655339 | 0.89 | JAK2 (0.50) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL1655371 | 0.87 | JAK2 (0.57) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL1655006 | 0.86 | JAK2 (0.49) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL1655141 | 0.84 | RPS6KA3 (0.56) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL1655057 | 0.84 | RPS6KA3 (0.58) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL4291720 | 0.82 | JAK2 (0.51) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL1655050 | 0.81 | JAK2 (0.49) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL1655250 | 0.81 | RPS6KA3 (0.55) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL13749253 | 0.81 | RPS6KA3 (0.55) | JAK2BRD4JAK3JAK1BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | claimed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | JAK2 2/4885BRD4 964/4885JAK3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.